Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 16, 2016 - Issue 2
Submit an article Journal homepage
280
Views
5
CrossRef citations to date
0
Altmetric
Reviews

The role of hyperthermia as a treatment for non-muscle invasive bladder cancer

Zaher BahouthDepartment of Urology, Bnai-Zion Medical Center, Faculty of Medicine, Technion- Institute of Technology, Haifa, IsraelCorrespondence[email protected]
,
Sarel HalachmiDepartment of Urology, Bnai-Zion Medical Center, Faculty of Medicine, Technion- Institute of Technology, Haifa, Israel
,
Boaz MoskovitzDepartment of Urology, Bnai-Zion Medical Center, Faculty of Medicine, Technion- Institute of Technology, Haifa, Israel
&
Ofer NativDepartment of Urology, Bnai-Zion Medical Center, Faculty of Medicine, Technion- Institute of Technology, Haifa, Israel
Pages 189-198 | Received 26 Aug 2015, Accepted 26 Nov 2015, Published online: 19 Dec 2015

References

• This article includes detailed guidelines on the treatment of NMIBC as written by the European Association of Urology

  • Sylvester RJ, van der MEIJDEN APM, Lamm DL. Intravesical bacillus calmette-guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970.
  • Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest oncology group study. J Urol. 2000;163(4):1124–1129.
  • Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin c versus bacillus calmette-guérin for non–muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256.
  • Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766–773.
  • Lammers RJM, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. Eur Urol. 2011;60(1):81–93.

• An important review of the literature, which included all studies, published before 2011

  • Maffezzini M, Campodonico F, Canepa G, et al. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. Cancer Chemother Pharmacol. 2014;73(5):925–930.
  • van der Heijden AG, Verhaegh G, Jansen CFJ, et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005;173(4):1375–1380.
  • Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol. 2001;52(3):273–278.

• An article that investigated the added effect of hyperthermia in the treatment of NMIBC, and investigated MMC pharmacokinetics

  • Colombo R, Brausi M, Da Pozzo LF, et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. Eur Urol. 2001;39(1):95–100.
  • Fiorito C, Milla P, Soria F, et al. Farmacocinetica, stabilità, tollerabilità e attività della MMC somministrata tramite un nuovo dispositivo per ipertermia (Unithermia®) in pazienti “BCG failures”. SIU. 2012.
  • Chou CK, Chen GW, Guy AW, et al. Formulas for preparing phantom muscle tissue at various radiofrequencies. Bioelectromagnetics. 1984;5(4):435–441.

• Its importance is in providing a model of “artificial bladder” that allowed others to investigate the in-vitro effects of cHT

  • Rigatti P, Lev A, Da Pozzo LF, et al. Locally induced hyperthermia in bladder cancer. In: Syrigos KN, Skinner DG, editors. Bladder cancer. Biology, diagnosis and management. oxford: Oxford Medical Publications; 1999. p. 393–406.
  • Rath-Wolfson L, Moskovitz B, Dekel Y, et al. Combined intravesical hyperthermia and mitomycin chemotherapy: a preliminary in vivo study. Int J Exp Pathol. 2003;84(3):145–152.
  • Uchibayashi T, Mihara S, Hirata A, et al. Experimental-study of radiofrequency capacitive hyperthermia on transplanted tumor. Int J Oncol. 1994;4(6):1301–1304.
  • Mauroy B, Bonnal JL, Prevost B, et al. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder]. Prog En Urol J Assoc Fr Urol Société Fr Urol. 1999;9(1):69–80.

• An in-vivo and in-vitro study that provided the safety and efficacy of cHT in animals

  • Colombo R, Lev A, Da Pozzo LF, et al. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol. 1995;153(3):959–963.
  • Juang T, Stauffer PR, Craciunescu OA, et al. Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer. Int J Hyperthermia. 2014;30(3):176–183.
  • Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur Urol. 1991;20(3):204–210.
  • Colombo R, Da Pozzo LF, Lev A, et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol. 1996;155(4):1227–1232.
  • Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol. 1998;159(3):783–787.
  • Colombo R, Pozzo LFD, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21(23):4270–4276.
  • Gofrit ON, Shapiro A, Pode D, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 2004;63(3):466–471.
  • Van Der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;46(1):65–72.
  • Moskovitz B. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol. 2005;16(4):585–589.
  • Halachmi S, Moskovitz B, Maffezzini M, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol Semin Orig Investig. 2011;29(3):259–264.
  • Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus calmette-guerin. J Urol. 2009;182(4):1313–1317.
  • Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC): RCT comparing thermochemotherapy with mitomycin-c alone as adjuvant treatment for NMIBC. BJU Int. 2011;107(6):912–918.

• Having the longest follow-up in the field, it is considered one of the most important studies that investigated cHT

  • Volpe A, Racioppi M, Bongiovanni L, et al. Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy? Urol Int. 2012;89(3):311–318.
  • Kiss B, Schneider S, Thalmann GN, et al. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?: Thermochemotherapy for superficial BC. Int J Urol. 2015;22(2):158–162.
  • Colombo R, Salonia A, Da Pozzo LF, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit Rev Oncol Hematol. 2003;47(2):127–139.
  • Sylvester RJ, Van Der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–477.
  • Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992;19(3):499–508.
  • Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol. 2001;40(2):144–150.
  • Gofrit ON, Pode D, Pizov G, et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy. Urol Oncol. 2009;27(3):258–262.
  • Joudi FN, Smith BJ, O’Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆. Urol Oncol Semin Orig Investig. 2006;24(4):344–348.
  • Bui TT, Schellhammer PF. Additional bacillus calmette-guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology. 1997;49(5):687–691.
  • Steinberg G, Bahnson R, Brosman S, et al.. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761–767.
  • Di Lorenzo G, Perdonà S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer. Cancer. 2010;116(8):1893–1900.
  • Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase ii trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus calmette-guérin. J Urol. 2013;190(4):1200–1204.
  • Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus calmette-guérin therapy. J Urol. 2013;189(3):834–839.
  • Alfred Witjes J, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party. World J Urol. 2009;27(3):319–324.
  • Shen Z, Shen T, Wientjes MG, et al. Intravesical treatments of bladder cancer: Review. Pharm Res. 2008;25(7):1500–1510.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.